Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy

European Archives of Psychiatry and Clinical Neuroscience

Volumn 254, Issue 5, 2004, Pages 303-311

  Zobel, Astrid ^a   Wellmer, Jörg ^b   Schulze Rauschenbach, Svenja ^a   Pfeiffer, Ute ^a   Schnell, Susanne ^a   Elger, Christian ^b   Maier, Wolfgang ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Cortisol; Depression; Dex CRH test; Dexamethasone; Epilepsy; HPA

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; ENZYME INDUCING AGENT; ETIRACETAM; GABAPENTIN; HYDROCORTISONE; LAMOTRIGINE; LIVER ENZYME; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADULT; AMYGDALOID NUCLEUS; ANTICONVULSANT THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DRUG BLOOD LEVEL; DRUG DEGRADATION; EPILEPSY; EPILEPTIC FOCUS; FEMALE; HIPPOCAMPUS; HORMONE RESPONSE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEGATIVE FEEDBACK; NEUROENDOCRINE DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; TEMPORAL LOBE;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; AREA UNDER CURVE; DEPRESSION; DEXAMETHASONE; EPILEPSY; FEEDBACK, BIOCHEMICAL; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MASS SPECTROMETRY; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 4744374209     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-004-0499-9     Document Type: Article

References (81)

1. Aliashkevich AF, Yilmazer-Hanke D, Van Roost D, Mundhenk B, Schramm J, Blumcke I (2003) Cellular pathology of amygdala neurons in human temporal lobe epilepsy. Acta Neuropathol 106:99-106
2. Altshuler L, Rausch R, Delrahim S, Kay J, Crandall P (1999) Temporal lobe epilepsy, temporal lobectomy, and major depression. J Neuropsych Clin N 11:436-443
3. Angehagen M, Ben-Menachem E, Ronnback L, Hansson E (2003) Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res 28:333-340
4. Bardeleben VU, Holsboer F (1989) Cortisol response to a combined dexamethasone-human corticotrophin-releasing hormone challenge in patients with depression. J Neuroendocrinol 1:485-488
5. Bauer J, Isojarvi JI, Herzog AG, Reuber M, Poison D, Tauboll E, Genton P, van d' V, Roesing B, Luef GJ, Galimberti CA, van Parys J, Flugel D, Bergmann A, Elger CE (2002) Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 73:121-125
6. Benedetti MS (2000) Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 14:301-319
7. Cacioppo JT, Berntson GG, Malarkey WB, Kiecolt-Glaser JK, Sheridan JF, Poehlmann KM, Burleson MH, Ernst JM, Hawkley LC, Glaser R (1998) Autonomic, neuroendocrine, and immune responses to psychological stress: the reactivity hypothesis. Ann NY Acad Sci 840:664-673
8. Checkley S (1996) The neuroendocrinology of depression and chronic stress. Brit Med Bull 52:597-617
9. Chrousos GP, Gold PW (1992) The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267:1244-1252
10. Cramer JA, Ben Menachem E, French J (2001) Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 47:17-25
11. Davies JA (1995) Mechanisms of action of antiepileptic drugs. Seizure 4:267-271
12. de Kloet ER (1995) Steroids, stability and stress. Front Neuroendocrin 16:416-425
13. Dinan TG (2001) Psychoneuroendocrinology of mood disorders. Curr Opin Psychiat 14:51-55
14. Drevets WC (2000) Neuroimaging studies of mood disorders. Biol Psychiatry 48:813-829
15. Drevets WC (2003) Neuroimaging abnormalities in the amygdala in mood disorders. Ann NY Acad Sci 985:420-444
16. Duclos M, Corcuff JB, Roger P, Tabarin A (1999) The dexamethasone- suppressed corticotrophin-releasing hormone stimulation test in anorexia nervosa. Clin Endocrinol 51:725-731
17. Elger CE, Schmidt D (1999) Arzneimittel auf einen Blick. In: Schmidt D, Elger CE (eds) Praktische Epilepsiebehandlung. Praxisorientierte Diagnose und Differentialdiagnose, rationale Therapiestrategien und handlungsorientierte Leitlinien. Georg Thieme Verlag, pp 47-57
18. Fassbender K, Schmidt R, Mossner R, Kischka U, Kuhnen J, Schwartz A, Hennerici M (1998) Mood disorders and dysfunction of the hypothalamic-pituitary- adrenal axis in multiple sclerosis - association with cerebral inflammation. Arch of Neurol 55:66-72
19. French JA, Gidal BE (2000) Antiepileptic drug interactions. Epilepsia 41(S8):S30-S36
20. Frodl T, Meisenzahl E, Zetzsche T, Bottlender R, Born C, Groll C, Jager, Leinsinger G, Hahn K, Moller HJ (2002) Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry 51:708-714
21. Gallagher BB (1987) Endocrine abnormalities in human temporal lobe epilepsy. Yale J Biol Med 60:93-97
22. George MS, Nahas Z, Bohning DE, Kozel FA, Anderson B, Chae JH, Lomarev, Denslow S, Li X, Mu C (2002) Vagus nerve stimulation therapy: a research update. Neurology 59:S56-S61
23. George MS, Nahas Z, Bohning DE, Lomarev M, Denslow S, Osenbach R, Ballenger JC (2000a) Vagus nerve stimulation: A new form of therapeutic brain stimulation. CNS Spectrums 5:43-52
24. George MS, Sackeim HA, Marangell LB, Husain MM, Nahas Z, Lisanby, Ballenger JC, Rush AJ (2000b) Vagus nerve stimulation. A potential therapy for resistant depression? Psychiat Clin North America 23:757-783
25. George MS, Sackeim HA, Rush AJ, Marangell LB, Nahas Z, Husain MM, Lisanby S, Burt T, Goldman J, Ballenger JC (2000c) Vagus nerve stimulation: a new tool for brain research and therapy. Biol Psychiatry 47:287-295
26. Grasser A, Möller A, Backmund H, Yassouridis A, Holsboer F (1996) Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis. Exp clin Endocr Diab 104:31-37
27. Harden CL (2002) The co-morbidity of depression and epilepsy: epidemiology, etiology, and treatment. Neurology 59:S48-S55
28. Hatzinger M, Z'Brun A, Hemmeter U, Seifritz E, Baumann F, Hosboer-Trachsler E, Heuser I (1995) Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. Neurobiol Aging 16:205-209
29. Heimer L (2003) A new anatomical framework for neuropsychiatric disorders and drug abuse. Am J Psychiatry 160:1726-1739
30. Henry TR (2002) Therapeutic mechanisms of vagus nerve stimulation. Neurology 59:S3-S14
31. Herman JP, Schafer KH, Sladek CD, Day R, Young EA, Akil H, Watson SJ (1989) Chronic electroconvulsive shock treatment elicits up-regulation of CRF and AVP mRNA in select populations of neuroendocrine neurons. Brain Res 501:235-246
32. Herzog AG (1989) A hypothesis to integrate partial seizures of temporal lobe origin and reproductive endocrine disorders. Epilepsy Res 3:151-159
33. Herzog AG (1999) Psychoneuroendocrine aspects of temporolimbic epilepsy. Part I Brain, reproductive steroids, and emotions. Psychosomatics 40:95-101
34. Heuser I, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F (1996) Pituitary-adrenal-system regulation and psychopathology during amitryptiline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 153:93-99
35. Heuser I, Yassouridis A, Holsboer F (1994) The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiat Res 28:341-356
36. Holsboer F (1998) Current theories on the pathophysiology of mood disorders. In: Montgomery S, Halbreich U (eds) Pharmacotherapy of mood and cognition. American Psychiatric Press Inc
37. Holsboer F (1999) Clinical neuroendocrinology. In: Charney DS, Nestler EJ, Bunny BS (eds) Neurobiology of mental illness. Oxford University Press 1999, pp 149-161
38. Holsboer F (2001) Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disorders 62:77-91
39. Holsboer F, Lauer C, Schreiber W, Krieg J (1995) Altered Hypothalamic-Pituitary-Adrenocortical Regulation in Healthy Subjects at High Familial Risk for Affective Disorders. Neuroendocrinology 62:340-347
40. Holsboer F, von Bardeleben U, Wiedemann, K, Muller OA, Stalla GK (1987) Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatry 22:228-234
41. Holsboer F, Wiedemann K, Gerken A, Boll E (1986) The plasma dexamethasone variable in depression: test-retest studies and early biophase kinetics. Psychiat Res 17:97-103
42. Holsboer-Trachsler E, Stohler R, Hatzinger M (1991) Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiat Res 38:163-171
43. Huesgen G, Roos C, Kinkeldei J (2000) Medikamentenbestimmung mit Elektrospray Tandem-Massenspektroskopie. J Lab Med 24:14-19
44. Hundt W, Zimmermann U, Pottig M, Spring K, Holsboer F (2001) The combined dexamethasone-suppression/CRH-stimulation test in alcoholics during and after acute withdrawal. Alcoholism: Clin Exp Res 25:687-691
45. Kudielka BM, Reinwald AK, Hellhammer DH, Kirschbaum C (1999) Psychological and endocrine responses to psychosocial stress and dexamethasone/corticotropin-releasing hormone in healthy postmenopausal women and young controls: The impact of age and a two-week estradiol-treatment. Neuroendocrinology 70:422-430
46. Kumpfel T, Then Bergh F, Friess E, Uhr, Yassouridis A, Trenkwalder C, Holsboer F (1999) Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis. Neuroendocrinology 70:431-438
47. Kunzel HE, Binder EB, Nickel T, Ising M, Fuchs B, Majer M, Pfennig A, Ernst G, Kern N, Schmid DA, Uhr M, Holsboer F, Modell S (2003) Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology 28:2169-2178
48. Lammers CH, Garcia-Borreguero D, Schmider J, Gotthardt U, Dettling M, Holsboer F, Heuser IJ (1995) Combined Dexamethasone/Corticotropin-Releasing Hormone test in patients with schizophrenia and in normal controls: II. Biol Psychiatry 38:803-807
49. McEwen BS (2000) Effects of adverse experiences for brain structure and function. Biol Psychiatry 48:721-731
50. McEwen BS (2001) Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann NY Acad Sci 933:265-277
51. McEwen BS, Gould E, Sakai R (1992) The vulnerability of the hippocampus to protective and destructive effects of glucocorticoids in relation to stress. Brit J Psychiat 160:18-24
52. Miller DB, O'Callaghan JP (2002) Neuroendocrine aspects of the response to stress. Metabolism 51:5-10
53. Modell S, Lauer CJ, Schreiber W, Huber J, Krieg JC, Holsboer F (1998) Hormonal response pattern in the combined Dex-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacol 18:253-262
54. Piazzini A, Canevini MP, Maggiori G, Ganger R (2001) Depression and anxiety in patients with epilepsy. Epilepsy Behav 2:481-489
55. Plotsky PM, Owens MJ, Nemeroff CB (1998) Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiat Clin North America 21:293-307
56. Pritchard PB (1991) The effect of seizures on hormones. Epilepsia 32(S6):S46-S50
57. Putignano P, Kaltsas GA, Satta MA, Grossman AB (1998) The effects of anti-convulsant drugs on adrenal function. Horm Metab Res 30:389-397
58. Quiske A, Helmstaedter C, Lux S, Elger CE (2000) Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 39:121-125
59. Rasmuson S, Andrew R, Nasman B, Seckl JR, Walker BR, Olsson T (2001) Increased glucocorticoid production and altered cortisol metabolism in women with mild to moderate Alzheimer's disease. Biol Psychiatry 49:547-552
60. Robertson MM, Coppen A, Trimble MR (1986) The dexamethasone suppression test in medicated epileptic patients. Biol Psychiatry 21:225-228
61. Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, Nahas Z, Haines S, Simpson RKJ, Goodman R (2000) Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 47:276-286
62. Rybakowski JK, Twardowska K (1999) The dexamethasone/corticotropin- releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiat Res 33:363-370
63. Sapolsky RM (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57:925-935
64. Sapolsky RM, Krey LC, McEwen BS (1986) The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev 7:284-301
65. Schachter SC (2002) Vagus nerve stimulation therapy summary: five years after FDA approval. Neurology 59:S15-S20
66. Schmider J, Lammers CH, Gotthardt U, Dettling M, Holsboer F, Heuser IJ (1995) Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I Biol Psychiatry 38:797-802
67. Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC (1996) Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. Neuropsychopharmacol 15:7-15
68. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder, AZ, Mintun MA (2001) Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 50:651-658
69. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW (1996) Hippocampal atrophy in recurrent major depression. Proc Nat Acad Sci USA 93:3908-3913
70. Shukla GD, Srivastava ON, Katiyar BC, Joshi V, Mohan PK (1979) Psychiatric manifestations in temporal lobe epilepsy: a controlled study. Br J Psychiatry 135:411-417
71. Sills GJ (2003) Pre-clinical studies with the GABAergic compounds vigabatrin and tiagabine. Epileptic Disord 5:51-56
72. Takeshita H, Kawahara R, Nagabuchi T, Mizukawa R, Hazama H (1986) Serum prolactin, cortisol and growth hormone concentrations after various epileptic seizures. Jap J Psychiat Neurol 40:617-623
73. Tecoma ES (1999) Oxcarbazepine. Epilepsia 40(S5):S37-S46
74. Then Bergh F, Kumpfel T, Grasser A, Rupprecht R, Holsboer F, Trenkwalder C (2001) Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. J Clin Endocr Metab 86:1610-1615
75. Treiman DM (2001) GABAergic mechanisms in epilepsy. Epilepsia 42(S3):8-12
76. Trimble MR, Mendez MF, Cummings JL (1997) Neuropsychiatric symptoms from the temporolimbic lobes. J Neuropsych Clin N 9:429-438
77. Vanitallie TB (2002) Stress: a risk factor for serious illness. Metabolism 51:40-45
78. Volk B, Meyer RP, von Lintig F, Ibach B, Knoth R (1995) Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. Toxicol Lett 82-83:655-662
79. Whysner J, Ross PM, Williams GM (1996) Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol Ther 71:153-191
80. Young EA, Spencer RL, McEwen BS (1990) Changes at multiple levels of the hypothalamo-pituitary adrenal axis following repeated electrically induced seizures. Psychoneuroendocrinol 15:165-172
81. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M (2001) Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiat Res 35:83-94